Perioperative teriparatide for preventing proximal junctional kyphosis and failure in patients with osteoporosis after adult thoracolumbar spinal deformity surgery: a prospective randomized controlled trial.

Park JH, Kwon O, Choi JH, Yeom JS, Park SM, Kim CH, Kim HJ

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA18 Mar 2025Cited by 4 (Europe PMC)

PMID40100350PMCIDPMC12089185DOI10.1007/s00198-025-07449-6PepBankPUB-40100350

Read at source PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients undergoing spinal deformity surgery, PJK incidence was 17.2% with teriparatide versus 33.3% with denosumab, without significant difference.
In plain wordsIn osteoporosis patients undergoing spinal deformity surgery, PJK rates did not differ significantly between teriparatide and denosumab.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeProximal junctional kyphosis
Study
n: not reported in source
Comparator
Denosumab
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 3 months preoperatively to 3 months postoperativelyAs given in this study (human).
Measurements
PJK incidence
17.2%
teriparatide
PJK incidence
33.3%
denosumab
Source sentences
Summary
The teriparatide group showed a lower incidence of PJK than the denosumab group (17.2% vs. 33.3%), although this difference was not statistically significant (p = 0.165 in a modified intention-to-treat (mITT) analysis).
3 context sentences(design, population, supporting numbers)
Summary · context
This randomized controlled trial is aimed at investigating and comparing the effects of perioperative teriparatide and denosumab as an active control for preventing proximal junctional kyphosis (PJK) and proximal junctional failure (PJF) in patients with osteoporosis after adult spinal deformity (ASD) surgery.
Summary · context
A total of 64 patients with osteoporosis, who planned to undergo ASD surgery, were randomly assigned to the teriparatide and denosumab groups.
Summary · context
Treatment with teriparatide or denosumab in both groups was conducted from 3 months preoperatively to 3 months postoperatively based on the standard regimen for each medication.
Report a problemFND-4010035001
02HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients undergoing spinal deformity surgery, PJF incidence was lower with teriparatide than denosumab, at 3.4% versus 22.2%.
In plain wordsIn osteoporosis patients undergoing spinal deformity surgery, PJF was less frequent with teriparatide than denosumab.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseProximal junctional failure
Study
n: not reported in source
Comparator
Denosumab
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 3 months preoperatively to 3 months postoperativelyAs given in this study (human).
Measurements
PJF incidence
3.4%
teriparatide
PJF incidence
22.2%
denosumab
Source sentences
Summary
Furthermore, the teriparatide group exhibited a significantly lower incidence of PJF than the denosumab group (3.4% vs. 22.2%; p = 0.034 in the mITT analysis).
3 context sentences(design, population, supporting numbers)
Summary · context
This randomized controlled trial is aimed at investigating and comparing the effects of perioperative teriparatide and denosumab as an active control for preventing proximal junctional kyphosis (PJK) and proximal junctional failure (PJF) in patients with osteoporosis after adult spinal deformity (ASD) surgery.
Summary · context
A total of 64 patients with osteoporosis, who planned to undergo ASD surgery, were randomly assigned to the teriparatide and denosumab groups.
Summary · context
Treatment with teriparatide or denosumab in both groups was conducted from 3 months preoperatively to 3 months postoperatively based on the standard regimen for each medication.
Report a problemFND-4010035002
03HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients after spinal deformity surgery, hip BMD did not differ significantly between teriparatide and denosumab at follow-up.
In plain wordsIn osteoporosis patients after spinal deformity surgery, hip bone density did not differ significantly between teriparatide and denosumab.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeHip BMD
Study
n: not reported in source
Comparator
Denosumab
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 3 months preoperatively to 3 months postoperativelyAs given in this study (human).
Source sentences
Summary
As for the secondary outcomes, no significant differences in BMD of the hip were observed between the two groups at the 1-year follow-up.
3 context sentences(design, population, supporting numbers)
Summary · context
This randomized controlled trial is aimed at investigating and comparing the effects of perioperative teriparatide and denosumab as an active control for preventing proximal junctional kyphosis (PJK) and proximal junctional failure (PJF) in patients with osteoporosis after adult spinal deformity (ASD) surgery.
Summary · context
A total of 64 patients with osteoporosis, who planned to undergo ASD surgery, were randomly assigned to the teriparatide and denosumab groups.
Summary · context
Treatment with teriparatide or denosumab in both groups was conducted from 3 months preoperatively to 3 months postoperatively based on the standard regimen for each medication.
Report a problemFND-4010035003
04HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients undergoing spinal deformity surgery, teriparatide improved postoperative back pain VAS compared with denosumab.
In plain wordsIn osteoporosis patients undergoing spinal deformity surgery, teriparatide improved back pain scores compared with denosumab.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreasePostoperative back pain VAS
Study
n: not reported in source
Comparator
Denosumab
Analysis
Secondary
Outcome group
Pain · Musculoskeletal
Studied dose
Dose not stated · 3 months preoperatively to 3 months postoperativelyAs given in this study (human).
Source sentences
Summary
The teriparatide group showed significantly improved postoperative VAS for back pain and EQ-5D score.
4 context sentences(design, population, supporting numbers)
Summary · context
The teriparatide group demonstrated significantly better PJF incidence and VAS for back pain, EQ-5D than the control group.
Summary · context
This randomized controlled trial is aimed at investigating and comparing the effects of perioperative teriparatide and denosumab as an active control for preventing proximal junctional kyphosis (PJK) and proximal junctional failure (PJF) in patients with osteoporosis after adult spinal deformity (ASD) surgery.
Summary · context
A total of 64 patients with osteoporosis, who planned to undergo ASD surgery, were randomly assigned to the teriparatide and denosumab groups.
Summary · context
Treatment with teriparatide or denosumab in both groups was conducted from 3 months preoperatively to 3 months postoperatively based on the standard regimen for each medication.
Report a problemFND-4010035004
05HumanRandomized controlled trialEfficacy outcome
In osteoporosis patients undergoing spinal deformity surgery, teriparatide improved postoperative EQ-5D scores compared with denosumab.
In plain wordsIn osteoporosis patients undergoing spinal deformity surgery, teriparatide improved EQ-5D scores compared with denosumab.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEQ-5D score
Study
n: not reported in source
Comparator
Denosumab
Analysis
Secondary
Outcome group
Quality of life · Musculoskeletal
Studied dose
Dose not stated · 3 months preoperatively to 3 months postoperativelyAs given in this study (human).
Source sentences
Summary
The teriparatide group showed significantly improved postoperative VAS for back pain and EQ-5D score.
4 context sentences(design, population, supporting numbers)
Summary · context
The teriparatide group demonstrated significantly better PJF incidence and VAS for back pain, EQ-5D than the control group.
Summary · context
This randomized controlled trial is aimed at investigating and comparing the effects of perioperative teriparatide and denosumab as an active control for preventing proximal junctional kyphosis (PJK) and proximal junctional failure (PJF) in patients with osteoporosis after adult spinal deformity (ASD) surgery.
Summary · context
A total of 64 patients with osteoporosis, who planned to undergo ASD surgery, were randomly assigned to the teriparatide and denosumab groups.
Summary · context
Treatment with teriparatide or denosumab in both groups was conducted from 3 months preoperatively to 3 months postoperatively based on the standard regimen for each medication.
Report a problemFND-4010035005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Perioperative teriparatide for preventing proximal junctional kyphosis and failure in patients with osteoporosis after adult thoracolumbar spinal deformity surgery: a prospective randomized controlled trial.

Summary

Results from this study5

Version history

Subjects

Publication types

MeSH terms

Keywords